Human complement factors and their therapeutic use

Details Human complement factors and their therapeutic use Human complement factors and their therapeutic use

1988-04-13

1989-11-28

Schain, Howard E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

424 9463, 424 9465, 424 9466, 424 9467, 514 2, 514 21, 530380, 530392, 530393, 530394, 530413, 530829, 530830, 530831, A61K 3704, A61K 3743

Patent

active

048837849

ABSTRACT:
The administration of Factor I and/or Factor H to a mammal has been found to alleviate or prevent such autoimmune diseases as systemic lupus erythematosus, rheumatoid arthritis and glomerulonephritis.

REFERENCES:
patent: 4308204 (1981-12-01), Becker et al.
patent: 4444757 (1984-04-01), Strausser
patent: 4618494 (1986-10-01), Angers
Immune Complex Disease in Experimental Animals and Man, Adv. Immunology 16 (1973), 186-204, C. G. Cochrane, D. Koffler.
A Spontaneous Rheumatoid Arthritis-Like Disease in MRL/1 Mice, J. Ex. Ped. 155, pp. 1690-1701, 1982, LeMing Hang, Argyrios N. Theofilopoulos, and Frank J. Dixon.
Alternative Pathway of Complement, Adv. Immunology, 29 (1.53) 1980, Hans J. Muller-Eberhard & Robert D. Schreiber.
Generation of Three Different Fragments of Bound C3 Wtih Purified Factor I or Serum, J. Immunology 129, pp. 2051-2060, 1982, Gordon D. Ross, John D. Lambris et al.
Biochem. J. (1982) vol. 203, pp. 293-298, Purification of Human C3b Inactivator by Monoclonal-Antibody Affinity Chromatography, Li-min Hsiung et al.
Proc. Natl. Acad. Sci. U.S.A. vol. 73, No. 9, pp. 3268-3272, Sep. 1976-Control of the Amplification Convertase of Complement by the Plasma Protein .beta.1H-John M. Weiler et al.
J. Exp. Med., vol. 148, pp. 1198-1215 (1978)-Spontaneous Murine Lupus.Like Syndromes-Brian S. Andrews et al.
J. Immunol., vol. 119, No. 4, pp. 1248-1252 (1977), Purification of C3b Inactivator and Demonstration of its Two Polypeptide Chain Structure-Douglas T. Fearon.
Biochem. J., vol. 191, pp. 173-182 (1980), Purification of the Human Complement Control Protein C3b Inactivator, L. Gail Crossley and Rodney R. Porter.
J. Immunol., vol. 125, pp. 578-582 (1980)-Cleavage of C4b by C3b Inactivator: Production of a Nicked Form of C4b, C4b', as an Intermediate Cleavage Product of C4b by C3b Inactivator-Shigeharu Nagasawa et al.
J. Exp. Med., vol. 144, pp. 1147-1163 (1976), Modulation of the Alternative Complement Pathway by .beta.1H Globulin, Keith Whaley and Shaun Ruddy.

Affiliated with

Also associated with

Rating

Human complement factors and their therapeutic use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human complement factors and their therapeutic use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human complement factors and their therapeutic use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-581861